Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Shoots for Annual 8% Growth through FY2025: 5-Year Plan
May 27, 2021
- Daiichi Sankyo’s Humira Biosimilar Now Available in Japan
May 27, 2021
- Takeda Stepping Up Work to Improve Japanese Ecosystem for Rare Diseases
May 27, 2021
- Sawai, Towa Post Domestic Sales Growth in FY2020, but Nichi-Iko Falters on GMP Violations: Jiho Tally
May 26, 2021
- Nihon Generic Recalling Ursodeoxycholic Acid Drug over Human Hair Contamination
May 25, 2021
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
- Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout
May 25, 2021
- Japan Ethical Drug Market Contracts 1% in Jan.-Mar.; Keytruda Top-Selling Drug for 8th Quarter Running: IQVIA
May 25, 2021
- Janssen Seeks Japan Approval for COVID-19 Vaccine
May 24, 2021
- Takeda’s CMV Drug Maribavir Gets FDA’s Priority Review
May 24, 2021
- Chugai’s FoundationOne Liquid Grabs Nod as Lynparza CDx
May 24, 2021
- AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
- Novo CEO Eyes 6-10% Annual Growth, Voices Hope for Rybelsus Tie-Up in Japan
May 20, 2021
- Third GPCR-Targeted Drug Enters Clinic under Sosei/Pfizer Collaboration
May 20, 2021
- Medicago’s COVID-19 Vaccine Yields Positive Interim Data: PII
May 20, 2021
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Janssen’s Darzquro, Chugai’s Polivy, JCR’s Izcargo Now Available in Japan
May 20, 2021
- Meiji Holdings Aims for 209 Billion Yen Pharma Sales in FY2023: New Biz Plan
May 20, 2021
- Nichi-Iko Chief to Take 50% Pay Cuts until Business Recovery
May 20, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…